Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Blood and Lymph Conditions

Gland and Hormone Related Diseases

Symptoms and General Pathology

Diseases and Abnormalities at or Before Birth

Rare Diseases

Uterine Cervical Neoplasms

Leukemia

Leukemia, Myeloid

Leukemia, Myeloid, Acute

Carcinoma

Adenocarcinoma

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Wilms Tumor

Cystadenocarcinoma, Serous

Uterine Cervical Dysplasia

Cystadenocarcinoma

Neoplasms by Histologic Type

Hematologic Diseases

Neoplasms, Glandular and Epithelial

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Cervical Diseases

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Myeloproliferative Disorders

Bone Marrow Diseases

Chronic Disease

Disease Attributes

Precancerous Conditions

Neoplasms, Cystic, Mucinous, and Serous

Myeloid Leukemia

Acute Myeloid Leukemia

Acute Non Lymphoblastic Leukemia

Ovarian Cancer

Cervical Intraepithelial Neoplasia

Chronic Graft Versus Host Disease

Ovarian Epithelial Cancer

Chronic Myeloid Leukemia

Acute Graft Versus Host Disease

Wilms' Tumor

Adenocarcinoma of the Appendix

Chronic Myeloproliferative Disorders

All Drugs and Chemicals

BIRC5 protein, human

Patient with histologically confirmed diagnosis of cervical cancer or cervical intraepithelial neoplasia (grade 3) or of high-grade serous (or undifferentiated) ovarian cancer or patients with AML or CML confirmed by bone marrow biopsy or peripheral blood Not treated - prior standard of care therapy acceptable one blood sampling performed on the visit day

Blood Sampling

Linda Mileshkin, MD

This study is a clinical study aiming at establishing immunological assays for the qualitative and quantitative evaluation of WT-1, Survivin and HPV16 E7-specific immune responses in cancer patients. Such a study will allow the development of suitable immunological tools to be used in assessing response in a subsequent phase I study aiming at evaluating therapeutic vaccine candidates targeting WT-1, Survivin and/or HPV16 E7-expressing tumors. In addition, this study will help defining the baseline cancer-associated immune responses in the selected patient population.

Cervical and ovarian cancer patients, as well as leukemia patients, will be included in this study.

WT-1, Survivin and HPV-specific immune responses will be monitored in these patients by ex vivo and cultured IFNg ELISpot as well as tetramer staining.

Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity

Phase 0 Study for the Development of Immunological Assays for the Evaluation of WT-1, Survivin and HPV16 E7 Tumor Antigens Specific Immune Responses in Cancer Patients

Direct and cultured IFNg ELISpot as well as direct tetramer staining assays will be set up and qualified for the detection WT-1, survivin and HPV16 E7 specific immune responses in cancer patients

Direct and Cultured IFNg ELISpot assays as well as tetramer staining assays will be used for the characterization of tumor specific immune responses in cancer patients

PX Biosolutions

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity	NCT02016833	Ovarian Serous ... Undifferentiate... Cervical Cancer Cervical Intrae... Acute Myeloid L... Chronic Myeloid...	Blood Sampling	18 Years - 70 Years	PX Biosolutions
Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity	NCT02016833	Ovarian Serous ... Undifferentiate... Cervical Cancer Cervical Intrae... Acute Myeloid L... Chronic Myeloid...	Blood Sampling	18 Years - 70 Years	PX Biosolutions

Spots Global Cancer Trial Database for cervical intraepithelial neoplasia, grade 3